BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37394414)

  • 1. Comparison and validation of different risk models for papillary renal cell carcinoma.
    Lin H; Sun Q; Li Z; Zheng J; Zhang X; Xiong Y; Chen H; Hou Y; Xi W; Lin J
    Urol Oncol; 2023 Aug; 41(8):358.e1-358.e7. PubMed ID: 37394414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
    Klatte T; Gallagher KM; Afferi L; Volpe A; Kroeger N; Ribback S; McNeill A; Riddick ACP; Armitage JN; 'Aho TF; Eisen T; Fife K; Bex A; Pantuck AJ; Stewart GD
    BMC Med; 2019 Oct; 17(1):182. PubMed ID: 31578141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma.
    Blackmur JP; Gaba F; Fernando D; Williams S; O'Donnell M; McNeill A; Stewart GD; Leung S; Laird A
    Urol Oncol; 2021 Jul; 39(7):438.e11-438.e21. PubMed ID: 34023196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.
    Palumbo C; Perri D; Zacchero M; Bondonno G; Martino JD; D'Agate D; Volpe A
    Urol Oncol; 2022 Apr; 40(4):167.e1-167.e7. PubMed ID: 35034803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of the VENUSS prognostic model to predict recurrence after surgery in non-metastatic papillary renal cell carcinoma: A multi-institutional analysis.
    Erdem S; Capitanio U; Campi R; Mir MC; Roussel E; Pavan N; Kara O; Klatte T; Kriegmair MC; Degirmenci E; Aydin R; Minervini A; Serni S; Berni A; Rebez G; Ozcan F;
    Urol Oncol; 2022 May; 40(5):198.e9-198.e17. PubMed ID: 35172939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data.
    Erdem S; Bertolo R; Campi R; Capitanio U; Amparore D; Anceschi U; Mir MC; Roussel E; Pavan N; Carbonara U; Kara O; Klatte T; Marchioni M; Pecoraro A; Muselaers S; Marandino L; Diana P; Borregales L; Palumbo C; Warren H; Wu Z; Calio A; Ciccarese C; Degirmenci E; Aydin R; Rebez G; Schips L; Simone G; Minervini A; Serni S; Ozcan F
    Urol Oncol; 2024 May; 42(5):163.e1-163.e13. PubMed ID: 38443238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study.
    Yang G; Nie P; Yan L; Zhang M; Wang Y; Zhao L; Li M; Xie F; Xie H; Li X; Xiang F; Wang N; Cheng N; Zhao X; Wang N; Wang Y; Chen C; Yun C; Cui J; Duan S; Zhang R; Hao D; Wang X; Wang Z; Niu H
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2949-2959. PubMed ID: 35344062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
    Laba P; Wang J; Zhang J
    BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
    Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
    Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis.
    Yang C; Shuch B; Kluger H; Humphrey PA; Adeniran AJ
    Am J Surg Pathol; 2020 May; 44(5):582-593. PubMed ID: 32101890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
    Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
    BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
    Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
    BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome.
    Cornejo KM; Dong F; Zhou AG; Wu CL; Young RH; Braaten K; Sadow PM; Nielsen GP; Oliva E
    Hum Pathol; 2015 Oct; 46(10):1411-7. PubMed ID: 26297250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative systemic inflammation response index indicates poor prognosis in patients treated with resection of renal cell carcinoma with inferior vena cava tumor thrombus.
    Lv Z; Feng HY; Wang T; Ma X; Zhang X
    Urol Oncol; 2022 Apr; 40(4):167.e9-167.e19. PubMed ID: 35042663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma.
    Ohsugi H; Yoshida T; Ohe C; Ikeda J; Sugi M; Kinoshita H; Tsuta K; Matsuda T
    Ann Surg Oncol; 2021 Apr; 28(4):2359-2366. PubMed ID: 32940805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
    Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
    BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma.
    Piccinelli ML; Tappero S; Cano Garcia C; Barletta F; Incesu RB; Morra S; Scheipner L; Tian Z; Luzzago S; Mistretta FA; Ferro M; Saad F; Shariat SF; Ahyai S; Longo N; Tilki D; Briganti A; Chun FKH; Terrone C; de Cobelli O; Musi G; Karakiewicz PI
    Eur Urol Open Sci; 2023 Jul; 53():109-115. PubMed ID: 37441347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathological features and prognostic analysis of papillary renal cell carcinoma].
    Bo ES; Hong P; Zhang Y; Deng SH; Ge LY; Lu M; Li N; Ma LL; Zhang SD
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):615-620. PubMed ID: 35950382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated staging systems for conventional renal cell carcinoma: a comparison of two prognostic models.
    Martella O; Galatioto GP; Necozione S; Pomante R; Vicentini C
    Arch Ital Urol Androl; 2011 Sep; 83(3):121-7. PubMed ID: 22184835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.